Bioniche Life Sciences Inc. Q2, Fiscal 2012 Conference Call and Audio Webcast
BELLEVILLE, ON, Feb. 9, 2012 - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that it will discuss its financial results for the second quarter of its 2012 fiscal year (ended December 31, 2011) during a:
Conference Call & Audio Webcast
Monday, February 13, 2012
5:00 p.m. (Eastern)
To participate in the conference call from North America, call (888) 231-8191 (conference ID: 44275811).
To participate in the conference call from Australia, call 1-800-287-011 (conference ID: 44275811).
A listen-only audio webcast will be available at:
A replay of the conference call will be available until February 20, 2012 at midnight by calling 1-855-859-2056 (passcode: 44275811).
The webcast will be available for replay using the above link until February 13, 2013.
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The fully-integrated company employs 214 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company’s primary goal is to develop proprietary cancer therapies supported by revenues from marketed products in human and animal health. Bioniche has been named one of the Top 50 Best Small and Medium-Sized Employers in Canada for 2010. For more information, please visit www.Bioniche.com.
Except for historical information, this news release may contain forward-looking statements that reflect the Company’s current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company’s ongoing quarterly and annual reporting.
For further information, please contact:
Jennifer Shea, Vice-President, Communications, Investor & Government Relations
Bioniche Life Sciences Inc.
Telephone: (613) 966-8058
Cell: (613) 391-2097